Tremelimumab | Interleukin Related interleukin-related.com

Product Name :
Tremelimumab

Search keywords :
Tremelimumab

drugId :
null

Target Vo:
Cytotoxic T-Lymphocyte-Associated Antigen 4

Target Vo Short Name :
CTLA4

Moa_Name:
Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors

First Approval Country :
United States

First Approval Date Filter:
2022

Origin Company_Name :
Pfizer Inc

Active Company_Name :
Astrazeneca Ab

Active Indication_Name:
Carcinoma, Non-Small-Cell Lung

In Active Indication_Name:
HIV Infections

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Cy3-conjugated AffiniPure Goat Anti-Mouse IgG H&L
Hsp90 alpha/beta Antibody
LAMP2 Antibody (YA310): LAMP2 Antibody (YA310) is a non-conjugated and Rabbit origined monoclonal antibody about 45 kDa, targeting to LAMP2. It can be used for WB,IHC-P assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts